Coherus Oncology, Inc. - 10-Q Filing
Coherus Oncology reports Q3 2026 financial results featuring revenue from Toripalimab and ongoing management of long-term debt obligations.
Tickers: $CHRS
Read the full article at SEC EDGAR
Part of the story Sable Offshore Corp. - 10-Q Filing (3 articles)